KR20220129548A - 생물제약 조성물 및 관련 방법 - Google Patents

생물제약 조성물 및 관련 방법 Download PDF

Info

Publication number
KR20220129548A
KR20220129548A KR1020227024058A KR20227024058A KR20220129548A KR 20220129548 A KR20220129548 A KR 20220129548A KR 1020227024058 A KR1020227024058 A KR 1020227024058A KR 20227024058 A KR20227024058 A KR 20227024058A KR 20220129548 A KR20220129548 A KR 20220129548A
Authority
KR
South Korea
Prior art keywords
seq
composition
antibody
heavy chain
variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227024058A
Other languages
English (en)
Korean (ko)
Inventor
켈리 닐론
밍쉬엔 장
Original Assignee
테사로, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테사로, 인코포레이티드 filed Critical 테사로, 인코포레이티드
Publication of KR20220129548A publication Critical patent/KR20220129548A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227024058A 2019-12-18 2020-12-10 생물제약 조성물 및 관련 방법 Pending KR20220129548A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962949696P 2019-12-18 2019-12-18
US62/949,696 2019-12-18
US201962950595P 2019-12-19 2019-12-19
US62/950,595 2019-12-19
PCT/US2020/064241 WO2021126657A1 (en) 2019-12-18 2020-12-10 Biopharmaceutical compositions and related methods

Publications (1)

Publication Number Publication Date
KR20220129548A true KR20220129548A (ko) 2022-09-23

Family

ID=74125707

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227024058A Pending KR20220129548A (ko) 2019-12-18 2020-12-10 생물제약 조성물 및 관련 방법

Country Status (11)

Country Link
US (1) US20230059341A1 (https=)
EP (1) EP4077388A1 (https=)
JP (2) JP2023507981A (https=)
KR (1) KR20220129548A (https=)
CN (1) CN115298218A (https=)
AU (2) AU2020407007A1 (https=)
BR (1) BR112022014694A2 (https=)
CA (1) CA3164600A1 (https=)
IL (1) IL293753A (https=)
MX (1) MX2022007464A (https=)
WO (1) WO2021126657A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI4076385T1 (sl) * 2019-12-20 2026-04-30 Formycon Ag Formulacije protiteles anti-pd1
WO2024118587A1 (en) * 2022-11-30 2024-06-06 Tesaro, Inc. Methods of treating cancer with anti-pd-1-antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015017307A2 (pt) * 2013-03-14 2017-11-21 Abbvie Inc composições de espécies com baixa acidez e métodos para produção e uso das mesmas
SMT202100065T1 (it) 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
FI3277321T3 (fi) 2015-04-01 2024-10-31 Anaptysbio Inc T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
KR20180037275A (ko) * 2015-08-24 2018-04-11 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 생물제약 조성물
CN106999591B (zh) * 2015-09-28 2021-02-23 苏州盛迪亚生物医药有限公司 一种抗pd-1抗体制剂及其在医药上的应用
LT3386541T (lt) * 2015-12-07 2020-10-26 Merck Patent Gmbh Vandeninė farmacinė kompozicija, apimanti anti-pd-1 antikūną avelumabą
JP2019533458A (ja) * 2016-11-01 2019-11-21 アナプティスバイオ インコーポレイティッド プログラム死１（ｐｄ−１）に対する抗体
AU2018206481B2 (en) 2017-01-09 2025-02-27 Tesaro, Inc. Methods of treating cancer with anti-PD-1 antibodies
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها

Also Published As

Publication number Publication date
AU2025203823A1 (en) 2025-06-19
JP2023507981A (ja) 2023-02-28
IL293753A (en) 2022-08-01
CN115298218A (zh) 2022-11-04
EP4077388A1 (en) 2022-10-26
AU2020407007A1 (en) 2022-06-23
CA3164600A1 (en) 2021-06-24
MX2022007464A (es) 2022-06-27
WO2021126657A1 (en) 2021-06-24
JP2026027328A (ja) 2026-02-18
US20230059341A1 (en) 2023-02-23
BR112022014694A2 (pt) 2022-09-06

Similar Documents

Publication Publication Date Title
JP2020504141A (ja) 抗ｐｄ−１抗体を用いてがんを処置する方法
CN115969970A (zh) Abcg2抑制剂与sacituzumab govitecan的组合
CN117222663A (zh) 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
IL293244B1 (en) Anti-icos agonist antibodies and uses thereof
JP2021521182A (ja) Ｃｄ７３アンタゴニストとｐｄ−１／ｐｄ−ｌ１軸アンタゴニストの組み合わせ治療
US20150259419A1 (en) Anti-MCAM Antibodies and Associated Methods of Use
TW202104270A (zh) 包含抗ｃｄ４７／ｐｄ－ｌ１雙特異性抗體的製劑及其製備方法和用途
JP2026027328A (ja) 生物医薬組成物および関連の方法
CN110546163A (zh) 抗-tigit抗原结合蛋白及其使用方法
CN112105388A (zh) 抗组织因子抗体-药物偶联物及其在癌症治疗中的应用
WO2017208210A1 (en) Anti-mcam antibodies and associated methods of use
TWI865617B (zh) 抗原結合蛋白
TW202233671A (zh) Ｐｅｇ結合抗ｍｅｒｔｋ抗體及其使用方法
JP7621340B2 (ja) 抗ｐｄ１抗体プロルゴリマブの水性医薬組成物およびその使用
TW202330027A (zh) 抗ｃｄ－４７抗體製劑
US20250340643A1 (en) Anti-CTLA Antibody Compositions and Related Methods
BR122024025522A2 (pt) Composições biofarmacêuticas, formulação, dispositivo de injeção, meio de cultura celular e eluato que compreendem as ditas composições e usos terapêuticos das mesmas
JP2024506931A (ja) Ｄｒ５結合性ポリペプチドの製剤
HK40083648A (zh) 生物藥物組合物和相關方法
WO2021023267A1 (zh) 包含抗pd-1/her2双特异性抗体的制剂及其制备方法和用途
CN118946583A (zh) 用t细胞接合分子治疗前列腺癌的联合治疗方法
WO2023185732A1 (zh) 包含抗Claudin18.2和CD3双特异性抗体的制剂及其制备方法和用途
TW202523359A (zh) 抗體-藥物結合物與抗pd-1/tim-3雙特異性結合蛋白質之組合
HK40093161A (zh) 抗ctla-4抗体药物组合物及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902